Patient P-01649
Therapy response
Stable
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Stable
Discontinuation risk
67%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −20% vs expected — Dietary Support Protocol NP-02
- Day 48 Tolerance state changed — Unstable → Improving
- Day 51 GI-04 recommended — GI Support Protocol GI-04
- Day 52 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 52 Patient accepted — Started GI-04 in the companion
- Day 60 GI symptom burden −31% vs expected — GI Support Protocol GI-04
- Day 66 Tolerance state changed — Unstable → Improving
- Day 67 ME-01 recommended — Monitoring Escalation ME-01
- Day 68 Patient accepted — Started ME-01 in the companion
- Day 71 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 52.
Primary contributors, last 14 days
- Toxicity+16
- Inflammatory activity+9
- Treatment adherence-8
- GI instability+5
- Nutritional resilience-3
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −20%
- GI Support Protocol GI-04Day 51Result: symptom burden −31%
- Monitoring Escalation ME-01Day 67Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
66%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 81% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 48
- Autonomic recovery ↓45
- WearableResting HR 73 bpm
- Wearable2,505 steps/day
- Inflammatory signalling ↑40
- BloodInflammatory load index 49
- WearableHRV 33 ms, trending down
- Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 35/100
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
DNA
Fictional pharmacogenomic panel
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.1 · butyrate capacity 35/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 36 ms
- Sleep
- 7.3 h
- Steps
- 3,266
- Resting HR
- 71 bpm
Daily log: GI score 40, nutritional resilience 53, adherence 47.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01377 | 25% | S11 | AD-05 | no change | 42 |
| P-01483 | 25% | S14 | AD-05 | no change | 35 |
| P-01679 | 25% | S12 | AD-05 | no change | 39 |
| P-01804 | 25% | S19 | AD-05 | improved | 61 |
| P-01689 | 25% | S13 | BR-03 | no change | 50 |
| P-01696 | 33% | S20 | CR-01 | improved | 59 |
| P-01371 | 32% | S06 | CR-01 | improved | 63 |
| P-01442 | 32% | S13 | CR-01 | improved | 61 |
| P-01388 | 29% | S17 | CR-01 | improved | 59 |
| P-01708 | 28% | S07 | CR-01 | improved | 59 |
| P-01835 | 28% | S17 | CR-01 | improved | 56 |
| P-01430 | 27% | S05 | CR-01 | improved | 54 |